Drug intelligence / Profile preview

Resultix

Development stage: Unknown
Lead developer: Dechra
Modality: Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

Resultix is a tick-killing spray developed for dogs and cats. The technology behind Resultix was created by Piedmont Pharmaceuticals. Bayer HealthCare's Animal Health Division collaborated with Piedmont Pharmaceuticals to bring the product to market, launching it for sale through veterinary clinics, pet specialty stores, and online retailers. It is designed to provide a convenient and easy-to-apply alternative for tick removal.

Brand names: Resultix

Beyond the preview

Go deeper on Resultix.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Resultix.